Cisplatin

About

Therapy type: Chemotherapy

Therapy strategy: Platinum-based chemotherapy

Mappings

NCI Thesaurus: Cisplatin (ncit:C376)

RxNorm: cisplatin (rxcui:2555, omop:4301188)

SNOMED: Cisplatin (sctid:387318005, omop:1397599)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (2) FDA (2) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
FDA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
FDA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
EMA (1) FDA (1) HSE (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
FDA (1)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
EMA (1)	HER2-positive	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
EMA (1)	HER2-positive	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
EMA (1)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
EMA (1)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Pembrolizumab
EMA (1) HSE (1)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (1)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab
EMA (1)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (2)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
EMA (1) HSE (2)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
EMA (1)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
EMA (1)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pemetrexed, Tislelizumab
HSE (1)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide
HSE (1)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (2)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
EMA (1)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Docetaxel, Nivolumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
EMA (1)	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
FDA (1)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
FDA (1)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (1)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
FDA (1)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab